Saphnelo (anifrolumab-fnia) is a prescription drug used to treat systemic lupus erythematosus. The drug comes as an intravenous (IV) infusion. It’s usually given once every 4 weeks by a healthcare ...

Saphnelo, a human monoclonal antibody, is a type 1 interferon (INF) receptor antagonist that inhibits a key protein in the immune system called the IFNAR receptor. This protein acts like a transmitter ...

Saphnelo may weaken a person’s immune system, potentially increasing their risk of infections. Mild side effects of Saphnelo include cough and infusion-related reactions, such as headache or fatigue.

The Food and Drug Administration has approved AstraZeneca's Saphnelo (anifrolumab-fnia) as a treatment for adults with systemic lupus erythematosus who are receiving standard therapy. It is the third ...

AstraZeneca has received approval from the US Food and Drug Administration (FDA) for the subcutaneous self-administration of Saphnelo (anifrolumab-fnia) using the Saphnelo Pen autoinjector for ...

WILMINGTON, Del.--(BUSINESS WIRE)--New subgroup analyses from the TULIP Phase III clinical trial program showed SAPHNELO (anifrolumab), a first-in-class type I interferon antagonist, in addition to ...

AstraZeneca’s SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus ...

Saphnelo’s (anifrolumab-fnia) dosage for lupus erythematosus is typically 300 milligrams every 4 weeks. Your dosage may vary based on your symptoms and other medications you may be taking. It’s ...